发明名称 USING BIOMARKER INFORMATION FOR HEART FAILURE RISK COMPUTATION
摘要 Provided is a method, system and/or apparatus for determining prospective heart failure event risk. Acquired from a device memory are a heart failure patient's current and preceding risk assessment periods. Counting detected data observations in the current risk assessment period for a current risk assessment total amount and counting detected data observations in the preceding risk assessment period for a preceding risk assessment period total amount. Associating the current risk assessment and preceding risk assessment total amounts with a lookup table to acquire prospective risk of heart failure (HF) event for the preceding risk assessment period and the current risk assessment period. Employing weighted sums of the prospective risk of the HF event for the preceding risk assessment period and the current risk assessment period to calculate a weighted prospective risk of the HF event for a patient. Displaying on a graphical user interface the weighted prospective risk of the HF event for the patient.
申请公布号 US2016206250(A1) 申请公布日期 2016.07.21
申请号 US201514964529 申请日期 2015.12.09
申请人 Medtronic, Inc. 发明人 Sharma Vinod;Warman Eduardo N.;Cho Yong K.;Sarkar Shantanu
分类号 A61B5/00;A61B5/0205;A61B5/145;A61B5/0432;A61B5/044 主分类号 A61B5/00
代理机构 代理人
主权项 1. A method of operation of a medical system for determining prospective heart failure event risk, the method comprising: (a) acquiring from a device memory a heart failure patient's current and preceding risk assessment periods; (b) counting detected data observations in the current risk assessment period for a current risk assessment total amount and counting detected data observations in the preceding risk assessment period for a preceding risk assessment period total amount; (c) associating the current risk assessment and preceding risk assessment total amounts with a lookup table to acquire prospective risk of heart failure (HF) event for the preceding risk assessment period and the current risk assessment period; (d) employing weighted sums of the prospective risk of the HF event for the preceding risk assessment period and the current risk assessment period to calculate a weighted prospective risk of the HF event for a patient; and (e) displaying on a graphical user interface the weighted prospective risk of the HF event for the patient.
地址 Minneapolis MN US